Photo taken from Susan Pandya/LinkedIn
Oct 31, 2023, 15:38
Susan Pandya: U.S. FDA approval of our targeted therapy underscores the efforts of our exceptional clinical research team
Susan Pandya, Vice President of Clinical Development and Global Head of Cancer Metabolism at Servier Pharmaceuticals, recently posted on LinkedIn.
“Today’s U.S. FDA approval of our targeted therapy in IDH1-mutated relapsed or refractory (R/R) myelodysplastic syndromes (MDS) underscores the efforts of our exceptional clinical research team, Servier Pharmaceuticals, in developing novel therapies for difficult and hard-to-treat cancers.
As the first and only approved targeted therapy for patients diagnosed with R/R MDS within this molecularly defined subset, this new indication reinforces the importance of mutational testing and its impact on improving patient outcomes.
View our full announcement here.”
Source: Susan Pandya/LinkedIn
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 8, 2025, 18:13
May 8, 2025, 17:53
May 8, 2025, 17:31
May 8, 2025, 17:30